UBS analyst Kevin Caliendo raised the firm’s price target on Cardinal Health (CAH) to $260 from $250 and keeps a Buy rating on the shares. The firm updated its model following the Q2 earnings report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $260 from $250 at Evercore ISI
- Cardinal Health price target raised to $235 from $222 at Mizuho
- Cardinal Health’s Earnings Call Highlights Broad-Based Upswing
- Early notable gainers among liquid option names on February 5th
- Morning Movers: Ralph Lauren and Qualcomm sink after earnings